Approval has been granted by Germany's Federal Institute for Drugs and Medical Devices (BfArM) for Silexion to commence the Phase 2/3 clinical trial of SIL204 in the country. This decision is supported by a favorable opinion from the Ethics Committee of the North Rhine Medical Association. The approval paves the way for the trial involving SIL204 to move forward in Germany.